Study #2021-0785
[HS-19-657]: A randomized, multi-center, open-label, active-controlled Phase 3 trial to assess the efficacy and safety of octreotide subcutaneous depot (CAM2029) versus octreotide LAR or lanreotide ATG in patients with gastroenteropancreatic neuroendocrin
MD Anderson Study Status
Not Accepting
Treatment Agent
CAM2029, Octreotide LAR, Lanreotide ATG
Description
The purpose of this study is to compare the effectiveness and safety of CAM2029 to octreotide LAR or lanreotide ATG in patients with advanced, well-differentiated GEP-NET. Patients who experience progressive disease in the randomized part of the study may proceed to an open-label extension part with intensified treatment with CAM2029.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Gastro-enteropancreatic Neuroendocrine Tumor
Study phase:
Phase III
Physician name:
James Yao
Department:
Gastrointestinal Medical Oncology
For general questions about clinical trials:
1-855-900-1058
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.